UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
PRINCETON, N.J., Aug. 17, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
GlobeNewsWire8/17/2026Neutral
URGN
UroGen Pharma LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.39B
P/E Ratio
—
EPS
$-2.01
Beta
1.57
52W High
$49.67
52W Low
$15.86
50-Day MA
$38.18
200-Day MA
$26.47
Dividend Yield
—
Profit Margin
-51.70%
Forward P/E
—
PEG Ratio
0.00
About UroGen Pharma Ltd
UroGen Pharma Ltd (URGN) is an innovative biotechnology company focused on the development of advanced therapies for urological diseases, including urothelial carcinoma and bladder cancer. Leveraging its proprietary reverse thermal gel technology, the company enables targeted, sustained drug delivery, maximizing treatment efficacy while reducing systemic side effects. UroGen's strong clinical pipeline underscores its commitment to addressing substantial unmet medical needs in the oncology space, positioning the company as a potential leader in the urological oncology market and significantly improving patient outcomes.
Fundamentals
| Revenue (TTM) | $188.73M |
| Gross Profit (TTM) | $171.46M |
| EBITDA | $-66.34M |
| Operating Margin | 0.15% |
| Return on Equity | -1481.00% |
| Return on Assets | -18.10% |
| Revenue/Share (TTM) | $3.81 |
| Book Value | $-2.71 |
| Price-to-Book | 19.27 |
| Price-to-Sales (TTM) | 12.69 |
| EV/Revenue | 12.95 |
| EV/EBITDA | -2.63 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 199.20% |
| Shares Outstanding | $48.72M |
| Float | $43.35M |
| % Insiders | 3.60% |
| % Institutions | 93.05% |
Historical Volatility
HV 10-Day
78.56%
HV 20-Day
72.14%
HV 30-Day
62.44%
HV 60-Day
52.37%
HV Rank
35.7%
Volatility is currently expanding
Analyst Ratings
Consensus ($60.00 target)
1
Strong Buy6
Buy1
HoldLatest News
Are You Looking for a Top Momentum Pick? Why Urogen Pharma (URGN) is a Great Choice
Does Urogen Pharma (URGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research8/14/2026Positive
Urogen Pharma Q2 Earnings Call Highlights
Urogen Pharma NASDAQ: URGN reported second-quarter 2026 revenue of $72.5 million, up from $24.2 million a year earlier, as the commercial launch of bladder cancer treatment ZUSDURI continued to gain traction. The company recorded a net loss of $14.4 million, or $0.28 per share, compared with a $49.9 million loss, or $1.05 per share, in the prior-year quarter.
MarketBeat8/5/2026Positive
UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript
UroGen Pharma Ltd. (URGN) Q2 2026 Earnings Call Transcript
Seeking Alpha8/5/2026Neutral
Urogen Pharma (URGN) Reports Q2 Loss, Tops Revenue Estimates
Urogen Pharma (URGN) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to a loss of $1.05 per share a year ago.
Zacks Investment Research8/5/2026Negative
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
ZUSDURI ® generated $50.4 million in revenue in the second quarter of 2026, representing 73% quarter-over-quarter growth Once issued, new U.S. patent is expected to provide protection into July 2044 for ZUSDURI and UGN-103 Continued advancement of pipeline, with UGN-103 on track for NDA submission in the third quarter of 2026 and UGN-501 expected to begin a Phase 1 trial in the fourth quarter of 2026 Conference call and webcast held today at 10:00 AM ET PRINCETON, N.J., Aug. 05, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
GlobeNewsWire8/5/2026Neutral
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, August 5th, 2026, at 10:00 AM ET
GlobeNewsWire7/29/2026Neutral
UroGen Pharma: Reimbursement Is Turning Zusduri Into A Workflow Moat
UroGen Pharma is shifting NMIBC treatment from surgery to office-based chemoablative therapy with ZUSDURI, driving a differentiated investment thesis. ZUSDURI revenue surged 109% sequentially to $29.2M in Q1 2026; repeat prescribers and workflow integration signal durable adoption and positive operating leverage. URGN's premium valuation is justified by a $5B+ TAM, durable clinical data, patent protection to 2044, and a de-risked pipeline including UGN-103.
Seeking Alpha7/20/2026Positive
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
PRINCETON, N.J., July 15, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd.
GlobeNewsWire7/15/2026Neutral
UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run
According to this Form 4 filing, the CMO of UroGen Pharma sold 10,000 shares at $40.00 per share, totaling $400,000 in transaction proceeds. The sale represented 8% of the insider's direct equity holdings in the company, as reported in the Form 4.
The Motley Fool7/12/2026Negative
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on URGN and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 8/18/2026